Cytokinetics CYTK Total debt

Total debt at other companies

Bristol-Myers SquibbBMY

$43.33B-12.3%

Eli LillyLLY

$54.91B+37.6%

Merck & Co.MRK

$49.1B+35.8%

Lexicon PharmaceuticalsLXRX

$59.24M-3.6%

Edgewise Therapeutics, Inc.EWTX

$3.79M-16.8%

Capricor TherapeuticsCAPR

$14.78M+1,083%

FAQ

What is Cytokinetics's total debt?

Cytokinetics (CYTK) reported total debt of $399.03M in Q2 2026.

How has Cytokinetics's total debt changed year-over-year?

Cytokinetics's total debt increased by 31.2% year-over-year, from $304.07M to $399.03M.

What is the long-term trend for Cytokinetics's total debt?

Over 5 years (2020 to 2025), Cytokinetics's total debt has grown at a 53.0% compound annual growth rate (CAGR), from $49.43M to $414.65M.

What does total debt mean?

Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.